MIRA · Mira Pharmaceuticals

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.

1200 Brickell Avenue, Miami, FL, 33131, United States
Drug Manufacturers - General
Healthcare

Market Cap

24.84M

52 Wk Range

$0.51 - $1.69

Previous Close

$0.59

Open

$0.59

Volume

585,000

Day Range

$0.33 - $0.59

Enterprise Value

19.92M

Cash

6.972M

Avg Qtr Burn

-1.299M

Insider Ownership

30.58%

Institutional Own.

6.27%

Qtr Updated

Sep 30th 2026